Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Simurosertib (TAK-931) is a selective and ATP-competitive cell division cycle 7 kinase inhibitor (IC50: <0.3 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 68.00 | |
2 mg | In stock | $ 97.00 | |
5 mg | In stock | $ 189.00 | |
10 mg | In stock | $ 263.00 | |
25 mg | In stock | $ 489.00 | |
50 mg | In stock | $ 713.00 | |
100 mg | In stock | $ 987.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 196.00 |
Description | Simurosertib (TAK-931) is a selective and ATP-competitive cell division cycle 7 kinase inhibitor (IC50: <0.3 nM). |
Targets&IC50 | CDC7:<0.3 nM |
In vitro | Simurosertib effectively inhibits CDC7 kinase activity (IC50 <0.3 nM) with time-dependent ATP-competitive kinetics to its ATP-binding pocket. Treatment with Simurosertib inhibits the cellular MCM2 phosphorylation at Ser40 in a dose-dependent manner, resulting in a delayed S phase progression, DNA-damage checkpoint activation, and caspase-3/7 activation. The selectivity studies using the 308 kinases reveals >120-fold selectivity of Simurosertib for CDC7 kinase inhibition compared to other kinase inhibitions [1]. |
In vivo | Simurosertib (p.o.) inhibits pMCM2 of the xenografted COLO205 in a dose- and time-dependent manner in the COLO205-xenograft mouse model. Simurosertib shows a significant antitumor activity in multiple xenograft models [1]. |
Synonyms | TAK-931 |
Molecular Weight | 341.43 |
Formula | C17H19N5OS |
CAS No. | 1330782-76-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 75 mg/mL (219.66 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Simurosertib 1330782-76-7 Cell Cycle/Checkpoint CDK Inhibitor anti-cancer TAK-931 Cyclin dependent kinase ATP-competitive TAK931 cycle cell orally inhibit TAK 931 division inhibitor